PMID- 15468329
OWN - NLM
STAT- MEDLINE
DCOM- 20050303
LR  - 20091211
IS  - 1552-4949 (Print)
IS  - 1552-4949 (Linking)
VI  - 62
IP  - 1
DP  - 2004 Nov
TI  - FISH cytogenetics and prognosis in breast and non-small cell lung cancers.
PG  - 52-6
AB  - BACKGROUND: Interphase cytogenetics by fluorescence in situ hybridization (FISH) 
      has been demonstrated to be a valuable diagnostic tool in effusions from patients 
      with solid tumors. As the next step, we investigated whether certain patterns of 
      numeric aberrations in malignant effusion cells supply prognostic information. 
      METHODS: From a large series of effusions from patients with solid tumors, 55 
      effusions from breast cancer and 39 effusions from non-small cell lung cancer 
      (NSCLC) were classified as malignant by cytology or FISH. Tumor cells were 
      classified as FISH aneuploid for chromosome 11 and/or 17 or as not aneuploid. 
      Predominant cytogenetic anomalies and patterns of intratumor cytogenetic 
      heterogeneity were brought in relation to overall survival rate. RESULTS: There 
      was no difference with respect to overall survival rate when effusions with or 
      without aneuploidy for chromosomes 11 and 17 were compared. Likewise, in 
      effusions with aneuploidy, there was no difference in overall survival rate among 
      patients with different modal chromosome copy numbers (e.g., trisomy vs. 
      tetrasomy 11) or among patients with a low or high grade of intratumor complexity 
      (defined by the intratumor heterogeneity of FISH aneuploidy). In breast cancer, 
      aneuploidy with gain of chromosome 11 was associated with a significantly 
      superior survival rate, suggesting that amplification of chromosome 11 DNA is 
      associated with a less aggressive phenotype. CONCLUSIONS: Simple chromosomal 
      changes as determined by FISH, such as gain of chromosome 11 copy numbers in 
      breast cancer, may be prognostic. Prospective studies in primary tumors that 
      classify distinct prognostic groups by FISH cytogenetics are warranted.
CI  - (c) 2004 Wiley-Liss, Inc.
FAU - Massoner, Anita
AU  - Massoner A
AD  - Department of Internal Medicine, Division of Hematology and Oncology, Medical 
      University of Innsbruck, Innsbruck, Austria.
FAU - Augustin, Florian
AU  - Augustin F
FAU - Duba, Hans-Christoph
AU  - Duba HC
FAU - Zojer, Niklas
AU  - Zojer N
FAU - Fiegl, Michael
AU  - Fiegl M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cytometry B Clin Cytom
JT  - Cytometry. Part B, Clinical cytometry
JID - 101235690
SB  - IM
MH  - *Aneuploidy
MH  - Breast Neoplasms/*genetics/mortality/pathology
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/mortality/pathology
MH  - Female
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*genetics/mortality/pathology
MH  - Pleural Effusion, Malignant
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 2004/10/07 09:00
MHDA- 2005/03/04 09:00
CRDT- 2004/10/07 09:00
PHST- 2004/10/07 09:00 [pubmed]
PHST- 2005/03/04 09:00 [medline]
PHST- 2004/10/07 09:00 [entrez]
AID - 10.1002/cyto.b.20023 [doi]
PST - ppublish
SO  - Cytometry B Clin Cytom. 2004 Nov;62(1):52-6. doi: 10.1002/cyto.b.20023.